Original Article

Effects of ischemic postconditioning on expressions of pentraxin-related protein 3 and neutrophil CD11b in the plasma of patients with acute myocardial infarction after percutaneous coronary intervention

Sheng-Hui Liu¹, Yu-E Huo², Xin-Wei Jia³, Ya Li⁴

ABSTRACT

Objective: To evaluate the effects of ischemic postconditioning on expressions of pentraxin-related protein 3 (PTX3) and neutrophil CD11b in the plasma of patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI).

Methods: Fifty-six patients who had AMI with ST-segment elevation were randomly divided into a control group and an ischemic postconditioning group (n=28). Both groups received emergency PCI. After recanalization of infarct-related arteries, the control group did not receive intervention within three minutes, while the ischemic postconditioning group was treated by low-pressure filling and emptying of balloon within one minute. The plasma expressions of PTX3 before and 24 hour after PCI were detected by ELISA, and those of neutrophil CD11b were detected by flow cytometry.

Results: PTX3 and neutrophil CD11b expressions of the two groups were similar before PCI, but those of the ischemic postconditioning group significantly decreased 24 hour after PCI (P<0.05).

Conclusion: Ischemic postconditioning lowered the expressions of PTX3 and neutrophil CD11b in AMI patients after PCI, inhibited inflammatory response, reduced the adhesion between leukocytes and endothelial cells, and protected the ischemic-reperfused myocardium.

KEY WORDS: Myocardial infarction, Ischemic postconditioning, Neutrophil, Cell adhesion molecule, Pentraxin-related protein 3.

INTRODUCTION

Ischemic postconditioning, which refers to several cycles of reperfusion-ischemia performed immediately after reperfusion, can protect the myocardium by decreasing infarct area and relieving reperfusion-induced arrhythmias.¹⁻³ On the other hand, inflammatory response plays an important role in the onset and progression of AMI. Whether ischemic postconditioning affects pentraxin-related protein 3 (PTX3) and CD11b as crucial inflammatory mediators has never been reported. Therefore, we aimed to assess the influence of ischemic postconditioning on PTX3 and CD11b expressions.

METHODS

Sampling and grouping: Fifty-six patients who had AMI with ST-segment elevation and treated in our hospital from June 2012 to December 2013 were selected, comprising 39 males and 17 females aged 36-73 years old. This study was approved by the ethics committee of our hospital, and written consent

1. Sheng-Hui Liu,
2. Yu-E Huo,
3. Xin-Wei Jia,
4. Ya Li,
1-4: Department of Cardiology, Affiliated Hospital of Hebei University, Baoding 071000, China.

Correspondence:
Yu-E Huo,
E-mail: huoyuedc@yeah.net

* Received for Publication: November 26, 2015
* Accepted for Publication: January 15, 2016

doi: http://dx.doi.org/10.12669/pjms.322.9457

How to cite this:
Liu SH, Huo YE, Jia XW, Li Y. Effects of ischemic postconditioning on expressions of pentraxin-related protein 3 and neutrophil CD11b in the plasma of patients with acute myocardial infarction after percutaneous coronary intervention. Pak J Med Sci. 2016;32(2):427-430. doi: http://dx.doi.org/10.12669/pjms.322.9457

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
has been obtained from all patients. The time from onset to emergency coronary angiography (CAG) was less than 12 hour. The patients complicated with old myocardial infarction, infections, systemic autoimmune disease, connective tissue diseases, tumors or liver and kidney dysfunction were excluded.

The patients were randomly divided into a control group and an ischemic postconditioning group (n=28), and both subjected to routine CAG and percutaneous coronary intervention (PCI). In the Ischemic postconditioning group, Infarct-related artery (IRA) was recanalized, blocked by primary balloon angioplasty (PTCA) for 30 s within one minute. after reperfusion, reperfused for another 30 seconds after emptying of the balloon. This procedure was repeated three times, after which a stent was inserted. Control group: IRA was recanalized, without any intervention within three minutes after reperfusion. Afterwards, routine operations were performed. The baseline clinical data of the two groups were similar (P>0.05) (Table-I).

Detection indices: Venous blood (3 ml) was collected before and 24 hour after PCI. Plasma PTX3 concentration was detected by ELISA, with the sensitivity of <0.15 μg/L. The reagents were purchased from ALEXIS (USA). Anticoagulated blood (100 μL) was added CD11b-PE antibody, reacted at room temperature in dark for 20 minutes, added 2 ml of lysis buffer to eliminate erythrocytes, and washed twice with phosphate buffer. Neutrophil CD11b expression was detected by flow cytometry (BD, USA). Fluorescent signals were obtained in logarithmic form to calculate the average fluorescent intensity. Creatine kinase isoenzyme (CK-MB) level was measured every four hour before and after PCI until maximum.

Statistical analysis: All data were analyzed by SPSS 11.5. The categorical data were expressed as mean ± standard deviation, and inter-group comparisons were performed with t test. The numerical data were compared by χ² test. P<0.05 was considered statistically significant, and P<0.01 was considered extremely statistically significant.

RESULTS

Maximum CK-MB levels: The ischemic postconditioning group had significantly lower maximum CK-MB level than that of the control group (116.5±31.49 vs 144.6±41.3 U/L) (P<0.05).

PTX3 and neutrophil CD11b expression levels: PTX3 and neutrophil CD11b expressions of the two groups were similar before PCI (P>0.05), but those of the ischemic postconditioning group significantly decreased 24 h after PCI (P<0.05) (Table-II).

| Group                   | Before PCI (CD11b) | 24 h after PCI (CD11b) | Before PCI (PTX-3) | 24 h after PCI (PTX-3) |
|-------------------------|--------------------|-------------------------|--------------------|------------------------|
| Control group (n=28)    | 405.62±61.63       | 498.71±83.78            | 6.06±3.17          | 7.36±4.25              |
| Ischemic postconditioning group (n=28) | 418.86±52.37       | 463.42±73.87*           | 6.13±3.69          | 6.58±4.18*             |

*P<0.05 vs. control group.

Table-I: Baseline clinical data.

| Clinical characteristics | Control group (n=28) | Ischemic postconditioning group (n=28) |
|--------------------------|----------------------|----------------------------------------|
| Age (year)               | 60.7±10.8            | 57.9±11.3                              |
| Male (case)              | 18 (64%)             | 21 (75%)                               |
| Hypertension (case)      | 16 (57%)             | 18 (64%)                               |
| Diabetic mellitus (case) | 6 (21.4%)            | 5 (17.8%)                              |
| Hyperlipidemia (case)    | 13 (46.4%)           | 15 (53.6%)                             |
| History of smoking (case)| 12 (42.9%)           | 14 (50%)                               |
| Infarct site             |                      |                                        |
| Anterior wall (case)     | 20 (71.4%)           | 22 (78.6%)                             |
| Posterior wall (case)    | 8 (28.6%)            | 6 (21.4%)                              |
| Time from onset to puncture (h) | 4.5±2.4            | 5.0±2.6                                |
| IRA                      |                      |                                        |
| Anterior descending artery (case) | 20 (71.4%) | 22 (78.6%)                             |
| Right coronary artery (case) | 6 (21.4%)           | 5 (17.9%)                              |
| Circumflex artery (case) | 2 (7.2%)             | 1 (3.5%)                               |

Table-II: PTX3 and neutrophil CD11b expression levels (mean±SD).
DISCUSSION

At the beginning of reperfusion, repeated, transient recanalization and reclosure of the coronary artery can alleviate ischemia-reperfusion injury and protect the myocardium, also known as ischemic postconditioning. By establishing a canine model of ischemia-reperfusion, Zhao et al.\(^1\) found that ischemic postconditioning protected the myocardium from reperfusion injury, which has been verified in many other animal models. In 2005, Staat et al.\(^3\) first proved that ischemic postconditioning exerted the same effect in clinical practice. Subsequently, it has been reported that ischemic postconditioning exerted long-term improving effects on the myocardial perfusion of AMI patients after PCI, and their cardiac function.\(^4,7\)

Ischemic postconditioning protects the heart by 1) improving hemodynamic indices (e.g. inhibiting the effects of myocardial infarction on blood pressure and heart rate), 2) decreasing infarct area, 3) reducing the release of myocardial enzymes (e.g. CK-MB and cTnl that mainly mark myocardial injury) and 4) mitigating free radical-induced myocardial injury.

As a member of the B2 integrin subfamily, CD11b mainly exists in neutrophils and monocytes, interacts with many types of ligands, and plays crucial roles in intercellular adhesion and inflammatory response. Under physiological conditions, it is only lowly expressed on the cell surface, which, however, increases obviously upon diseases.\(^8\) Since AMI is commonly accompanied by inflammatory response, neutrophil CD11b expression is bound to increase,\(^9,10\) which then mediates the migration of numerous neutrophils to tissues around the related blood vessels by interacting with cell adhesion molecule ICAM-1 expressed in ligand-endothelial cells. As a result, cardiomyocytes are injured due to released oxygen radicals, platelet activating factor, collagenase, elastase, cathepsin, proteolytic enzymes and lipid metabolites.\(^11\)

PTX3, as a newly discovered acute-phase protein upon inflammation, belongs to the hs-CRP superfamily. Michael et al.\(^12\) reported that PTX3 was highly expressed in AMI patients. By using immunohistochemical assays, Muller et al.\(^13\) found that pro-inflammatory cytokines such as LPS, IL-1b and TNF-α induced main pro-atherosclerotic cells (i.e. endothelial cells and monocytes) and cardiomyocytes to express PTX3, being closely associated with the onset and progression of inflammatory heart diseases. Inoue et al.\(^14\) reported that the expression level of PTX3 at the edge of atherosclerotic plaques exceeded that in the center, suggesting that activation of these plaques was positively correlated with PTX3 level. Latini et al.\(^15\) demonstrated that serum PTX3 could predict the 3-month mortality rate of AMI patients with ST-segment elevation, as a risk stratification predictor for death after myocardial infarction. Moreover, plasma PTX3 levels of patients with unstable angina and AMI patients with ST-segment elevation were measured within 24 h after chest pain, showing that PTX3 was positively correlated with the probability of cardiovascular events within 6 months and able to reflect local vascular inflammation and damage of the cardiovascular system.\(^16\)

In summary, ischemic postconditioning decreased the expressions of PTX3 and neutrophil CD11b in AMI patients after PCI, and suppressed inflammatory response, thus relieving myocardial injury finally.

Source of funding: None.

Declaration of Interest: The authors declare no conflicts of interest.

REFERENCES

1. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285(2):H579-H588.
2. Galagudza M, Kuraeev D, Minasian S, Valen G, Vaage J. Ischemic postconditioning: brief ischemia during reperfusion converts persistent ventricular fibrillation into regular rhythm. Eur J Cardiothorac Surg. 2004;25(6):1006-1010.
3. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L’Huillier I, et al. Post conditioning the Human Heart. Circulation. 2005;112(14):2143-2148.
4. Yang XC, Liu Y, Wang LF, Cui L, Wang T, Ge YG, et al. Reduction in myocardial infarction by postconditioning after primary coronary angioplasty. J Invasive Cardiol. 2007;19(10):424-430.
5. Ma X, Zhang X, Li C, Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial function and lv recovery after myocardial infarction. J Interv Cardiol. 2006;19(3):367-375.
6. Laskey WK, Yoon S, Calzada N, Ricciardi MJ. Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a benefit of postconditioning. Catheter Cardiovasc Interv. 2008;72(2):212-220. doi: 10.1002/ccd.21583.
7. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, et al. Long-term benefit of postconditioning. Circulation. 2008;117(8):1037-1044. doi: 10.1161/CIRCULATIONAHA.107.729780
8. Rea IM, McNerlan SE, Alexander DH, Armstrong ME. Blood pressure and TNF-α act synergistically to increase leucocyte CD11b adhesion molecule expression in the BELFAST study: implications for better blood pressure control in ageing. Age (Dordr). 2013;35(1):197-205. doi: 10.1007/s11357-011-9526-1.

9. Chen DH, Zhang QH, Wei SS, Huang P, Wu SL, Feng JZ. Study of expression of adhesion molecules on neutrophils in elderly patients with acute myocardial infarction and their impact of fibrinolytic therapy. Chinese J Geriatrics. 2005;24(11):828-830.

10. Yao T, Lu W, Zhu J, Jin X, Ma G, Wang Y, et al. Role of CD11b+Gr-1+ myeloid cells in AGEs-induced myocardial injury in a mice model of acute myocardial infarction. Int J Clin Exp Pathol. 2015;8(3):3238-3249.

11. Wiedermann CJ, Schratzberger P, Kähler CM. Migration of neutrophils across endothelial monolayers is stimulated by treatment of the monolayers with beta-endorphin. Brain Behav Immun. 1994;8(3):270-277.

12. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22(5):e10-14.

13. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001;29(7):1404-1407.

14. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007;27(1):161-167.

15. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110(16):2349-2354.

16. Matsu S, Ishii J, Kitagawa F, Kuno A, Hattori K, Ishikawa M, et al. Pentraxin 3 in unstable angina and non ST segment elevation myocardial infarction. Atherosclerosis. 2010;210(1):220-225. doi: 10.1016/j.atherosclerosis.2009.10.033.

Authors’ Contributions:

SHL & YEH: Study design and manuscript writing.
XWJ & YL: Data collection and analysis.